跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 42 条关于
“KAT5”
全部
42
临床试验
9
药物
22
机构
2
资讯
9
9个月前
IDEAYA Biosciences Submits IND for First-in-Class KAT6/7 Dual Inhibitor IDE574 Targeting Breast and Lung Cancers
去年
Closed Loop Medicine Appoints Kate Woolland as CEO to Drive Precision Dosing Commercialization
去年
Olema's KAT6 Inhibitor OP-3136 Shows Promising Anti-Tumor Activity Across Multiple Cancer Types
29天前
EverGlade Adds Former ARPA-H Scientific Advisor Kate Teffer to Expand Federal Health Research Capabilities
去年
Tailored EHR Alerts Fail to Improve AKI Management in Hospitalized Patients: KAT-AKI Trial
去年
Olema Oncology's KAT6 Inhibitor OP-3136 Receives FDA IND Clearance, Phase 1 Trial Planned for 2025
去年
Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 to Phase 3 Trial for HR+/HER2- Metastatic Breast Cancer
11个月前
Kynexis Initiates Phase 2 Trial of First-in-Class KAT-II Inhibitor for Schizophrenia-Associated Cognitive Impairment
上个月
Kynexis Extends Series A to €97 Million to Advance First-in-Class KAT-II Inhibitor for Cognitive Impairment in Schizophrenia